Logo

NRSN

NeuroSense Therapeutics Ltd.

NRSN

NeuroSense Therapeutics Ltd. • NASDAQ
$1.19 ▲ 1.71% (+0.02)
Market Cap $29.35 M
52w High $2.60
52w Low $0.81
Dividend Yield 0%
P/E -3.31
Volume 70.83K
Outstanding Shares 24.67M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $0 $2.346M $-2.354M 0% $-0.093 $-2.342M
Q1-2025 $0 $2.346M ▲ $-2.354M ▼ 0% $-0.093 ▼ $-2.342M ▼
Q4-2024 $0 $1.771M ▼ $-1.801M ▲ 0% $-0.083 ▲ $-1.766M ▲
Q3-2024 $0 $2.107M ▼ $-2.148M ▼ 0% $-0.11 ▼ $-2.102M ▲
Q2-2024 $0 $3.03M $-857K 0% $-0.048 $-3.025M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $666K $1.684M $2.203M $-519K
Q1-2025 $666K ▼ $1.684M ▼ $2.203M ▲ $-519K ▼
Q4-2024 $3.378M ▲ $4.575M ▲ $1.992M ▼ $2.583M ▲
Q3-2024 $344K ▼ $984K ▼ $3.802M ▲ $-2.818M ▼
Q2-2024 $1.243M $1.841M $3.544M $-1.703M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-2.354K $-2K $-6.5 $650.5 $0 $-2K
Q1-2025 $-2.354K ▼ $-2K ▼ $-6.5 ▼ $650.5 ▲ $0 $-2K ▼
Q4-2024 $-1.801K ▲ $0 $0 $0 $0 $0
Q3-2024 $-2.148K ▼ $0 $0 $0 $0 $0
Q2-2024 $-857 $0 $0 $0 $0 $0

Five-Year Company Overview

Income Statement

Income Statement NeuroSense is still a pure research-stage biotech company, so it does not generate product revenue yet. Its income statement mainly reflects ongoing R&D and operating costs, which lead to steady annual losses. Those losses have been relatively consistent over the last few years, suggesting a controlled spend rather than a rapid ramp-up, but the business is clearly in an investment phase, not an earning phase. Earnings per share have been negative every year, which is typical for a small clinical‑stage biotech but means current value depends entirely on future clinical and regulatory success, not on existing cash flow or profits.

Balance Sheet

Balance Sheet The balance sheet is very light, with modest assets and cash and no meaningful debt reported. This points to a lean structure but also highlights financial fragility: the company does not appear to have a large capital cushion to fund many years of trials on its own. Equity represents essentially all of the capital, which is typical for early biotechs that rely on equity funding rather than borrowing. The absence of debt reduces financial pressure from interest payments, but the small asset base underscores ongoing dependence on future fundraising or partnerships.

Cash Flow

Cash Flow Cash flows show a simple picture: money is flowing out to fund operations and R&D, with no offsetting inflows from product sales. Operating cash outflows have been fairly stable, implying disciplined spending, and capital expenditures are minimal, which fits a research-focused, asset‑light model. However, with no internal cash generation, the company’s ability to maintain its programs hinges on access to capital markets or strategic partners. Any delay or setback in clinical timelines could quickly tighten the cash situation.

Competitive Edge

Competitive Edge NeuroSense aims to carve out a niche in neurodegenerative diseases—especially ALS—by using combination therapies that attack several disease mechanisms at once. That approach differentiates it from many competitors that focus on single targets or narrow genetic subtypes. Its lead drug candidate, PrimeC, has shown encouraging mid-stage trial data in ALS and benefits from orphan drug status and long patent protection, which together can help create a commercial moat if late-stage results confirm the benefit. Still, the company operates in a crowded, high‑stakes field with larger, better‑funded rivals and intense scientific uncertainty, so its competitive position is promising but far from assured and highly dependent on the success of its pivotal trial and on securing strong partners.

Innovation and R&D

Innovation and R&D Innovation is the core of NeuroSense’s story. The company is pioneering a multi-target, combination‑therapy approach using known drugs in new ways, aiming to address inflammation, iron imbalance, and microRNA disruptions all at once in ALS. It is also investing in digital biomarkers through collaborations, which could make its trials more precise and attractive to regulators and partners. Beyond ALS, the pipeline extends the same combination‑therapy logic to Alzheimer’s and Parkinson’s in early-stage programs, suggesting a platform mindset rather than a one‑off product. The main risk is classic for biotech: heavy reliance on a small number of programs, long development timelines, and binary trial outcomes, but the R&D strategy is clearly focused and differentiated.

Summary

NeuroSense is an early-stage biotech with no revenue, recurring losses, and a very lean balance sheet, which makes it financially dependent on external funding and partnerships. The investment thesis centers almost entirely on its science: a differentiated combination‑therapy platform targeting complex neurodegenerative diseases, led by PrimeC in ALS with encouraging mid‑stage data and meaningful regulatory and patent support. Success in the upcoming pivotal trial and in securing a capable commercial or development partner would be transformative; setbacks would be difficult to absorb given the limited financial resources. Overall, this is a high‑risk, high‑uncertainty profile typical of small clinical‑stage biotechs, where future outcomes hinge on a few key clinical and regulatory milestones rather than current financial performance.

NEWS

November 24, 2025 · 9:56 AM UTC

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

Read more

November 3, 2025 · 9:15 AM UTC

NeuroSense to Host Investor Webinar on December 8, 2025

Read more

October 6, 2025 · 9:00 AM UTC

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

Read more

September 10, 2025 · 2:30 PM UTC

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

Read more

September 4, 2025 · 8:49 AM UTC

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

Read more